Anti-platelet or anti-coagulant agent for prevention of ischemic stroke in patients with end-stage renal disease and atrial fibrillation, is it necessary?
Journal
International Journal of Cardiology
Journal Volume
196
Pages
53
Date Issued
2015
Author(s)
SDGs
Other Subjects
acetylsalicylic acid; anticoagulant agent; antithrombocytic agent; clopidogrel; ticlopidine; warfarin; anticoagulant agent; antithrombocytic agent; anticoagulant therapy; atrial fibrillation; bleeding tendency; brain hemorrhage; brain ischemia; CHADS2 score; drug effect; end stage renal disease; high risk patient; human; Letter; long term care; neuroprotection; priority journal; propensity score; proportional hazards model; atrial fibrillation; brain ischemia; female; Kidney Failure, Chronic; male; Stroke; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Female; Humans; Kidney Failure, Chronic; Male; Platelet Aggregation Inhibitors; Stroke
Publisher
Elsevier Ireland Ltd
Type
journal article